Climb Bio Presents Initial Phase 2 Data for Budoprutug in pMN

At 200 mg, budoprutug demonstrated B-cell depletion, PLA2R antibody reduction and immunologic remission at 12 weeks. The company said additional PrisMN Phase 2 data are anticipated; 200 mg and 600 mg doses have been generally well tolerated.